Atlas Venture Advisors’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Atlas Venture Advisors’s Portfolio FSTX Stock Details FSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-574,996	Closed	-$3.63M	–	7
2022 Q4	$3.63M	Hold	574,996	–	–	1.25%	4
2022 Q3	$2.94M	Hold	574,996	–	–	1.06%	5
2022 Q2	$3.6M	Hold	574,996	–	–	1.14%	4
2022 Q1	$2.04M	Hold	574,996	–	–	0.44%	6
2021 Q4	$2.89M	Hold	574,996	–	–	0.4%	7
2021 Q3	$4.21M	Hold	574,996	–	–	0.5%	6
2021 Q2	$4.94M	Hold	574,996	–	–	0.51%	7
2021 Q1	$6.23M	Hold	574,996	–	–	1.15%	6
2020 Q4	$5.67M	Buy	+574,996	New	+$3.76M	1.27%	7

Atlas Venture Advisors's FSTX Position: Q1 2023 in Review

Atlas Venture Advisors sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2023, closing a stake of 574,996 shares — an estimated $3.63M sold.

Atlas Venture Advisors first reported a position in FSTX in Q4 2020 and held it in 9 quarters. The position peaked at $6.23M in Q1 2021. 0 funds tracked by Wall St. Rank hold FSTX as of Q1 2023.

Atlas Venture Advisors reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Atlas Venture Advisors sold 574,996 F-star Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $3.63M.
Atlas Venture Advisors first reported a position in F-star Therapeutics, Inc. Common Stock in Q4 2020 and held it in 9 quarters.
Atlas Venture Advisors's F-star Therapeutics, Inc. Common Stock position peaked at $6.23M in Q1 2021.
0 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Atlas Venture Advisors's 13F filing for Q1 2023, filed 8 May 2023.